5月22日，派格生物医药-B(02565)盘中上涨7.54%，报13.81港元，成交额3346.31万港元，在前一交易日下跌5.14%后出现反弹。
消息面上，派格生物此前与腾瑞制药就核心产品派达康（维培那肽注射液）签署中国大陆独家商业化战略合作协议，确立累计销售规模超100亿元人民币的核心目标，腾瑞制药将支付约1.4亿港元权益金。5月12日，方舟健客与腾瑞制药签署战略合作，派达康将在其互联网医院平台全网首发。该股自5月18日单日飙升超100%后持续波动，市场关注5月27日全面解禁带来的抛压风险。
派格生物医药是一家专注慢性病创新疗法的公司，核心产品PB-119为中国国内最早研发的长效GLP-1受体激动剂之一，主要覆盖2型糖尿病、肥胖症等代谢疾病领域。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.